Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsASX:CUV +3.23%84 Return-on-Tangible-Asset is 7.72% as of Dec. 2025, which is 63% below its 10-year median of 20.68. GuruFocus rates ASX:CUV with a GF Score™ of 84/100 and a GF Value™ of A$17.79 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 92.09% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Clinuvel Pharmaceuticals's annualizedNet Income for the quarter that ended in Dec. 2025 was A$20.89 Mil. Clinuvel Pharmaceuticals's average total tangible assets for the quarter that ended in Dec. 2025 was A$270.54 Mil. Therefore, Clinuvel Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 7.72%.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
ASX:CUV'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -18.67 Med: 20.68 Max: 37.08
Current: 12.56
During the past 13 years, Clinuvel Pharmaceuticals's highest Return-on-Tangible-Asset was 37.08%. The lowest was -18.67%. And the median was 20.68%.
ASX:CUV's Return-on-Tangible-Asset is ranked better than 92.09% of 1416
companies
in the Biotechnology industry
Industry Median: -35.915
vs ASX:CUV: 12.56
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Clinuvel Pharmaceuticals Return-on-Tangible-Asset Related Terms
Clinuvel Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Clinuvel Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.72% mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a Return-on-Tangible-Asset of 7.72% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 63% below median its historical median of 20.68. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #112 out of 1416 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Clinuvel Pharmaceuticals' Return-on-Tangible-Asset too high?
Clinuvel Pharmaceuticals' current Return-on-Tangible-Asset of 7.72% is 63% below median its 10-year median of 20.68. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #112 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #112 out of 1416 companies for Return-on-Tangible-Asset. This places Clinuvel Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Return-on-Tangible-Asset is 7.72%, which is 63% below median its own 10-year median of 20.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.79, compared to a current price of A$10.24 — trading 42.4% below its estimated fair value. The current Return-on-Tangible-Asset is 7.72%, which is 63% below median its 10-year median of 20.68. Clinuvel Pharmaceuticals' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Return-on-Tangible-Asset is 7.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.24 is trading 42.4% below its estimated GF Value™ of A$17.79.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Return-on-Tangible-Asset: 7.72% (63% below median its 10-year median of 20.68)
GF Value™: A$17.79 vs. price of A$10.24 (42.4% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
84GF Score
Get the complete analysis for ASX:CUV
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
